KDM1A and acute myeloid leukemia: Indeed, using the published HiChIP data43, we detected significant reduction of long-range chromatin interactions between the MYC promoter and PVT1 enhancers after LSD1 inhibitor (LSD1i, GSK-LSD1) treatment in murine AF9 BETi-resistant AML cells (Fig. 7f).